Sec. 1. Short title; table of contents
140 words·~1 min read·
/bill/118/s/1269/is/section-1·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
This Act may be cited as the or the Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2023 . INSULIN Act of 2023 The table of contents for this Act is as follows: Sec. 1. Short title; table of contents. TITLE I—Commercial market patient protections Sec. 101. Requirements with respect to cost-sharing for certain insulin products. Sec. 102. Application to retiree and certain small group plans. Sec. 103. Administration. TITLE II—Pharmacy benefit manager transparency and rebate reform Sec. 201.
Full rebate on insulin pass-through to plan. TITLE III—Biosimilar biological product and generic drug competition and affordability Sec. 301. Ensuring timely access to generics. Sec. 302. Permitted mid-year changes in Medicare part D plan formularies for certain biosimilar biological products and the reference product of such biosimilars. Sec. 303. Expediting competitive biosimilar competition. Sec. 304. Insulin competition report.